Dysmenorrhea.

Area of Science:

• Gynecology
• Pain Management
• Pharmacology

Background:

• Dysmenorrhea affects over 50% of menstruating women, causing significant personal, public health, and economic burdens.
• Primary dysmenorrhea lacks identifiable pelvic pathology, while secondary dysmenorrhea is linked to underlying pelvic conditions.
• The pathophysiology of primary dysmenorrhea involves excessive uterine prostaglandin production, leading to abnormal uterine activity and pain.

Purpose of the Study:

• To review the pathophysiology of dysmenorrhea, differentiating between primary and secondary types.
• To discuss effective treatment strategies for both primary and secondary dysmenorrhea.
• To highlight the role of prostaglandin inhibitors and hormonal contraceptives in managing dysmenorrhea.

Main Methods:

• Literature review of dysmenorrhea pathophysiology and treatment options.
• Analysis of the mechanisms of action for nonsteroidal anti-inflammatory drugs (NSAIDs) and oral contraceptives.
• Evaluation of diagnostic criteria and treatment indications for dysmenorrhea.

Main Results:

• Prostaglandin synthetase inhibitors (NSAIDs) effectively reduce pain and menstrual fluid prostaglandins in primary dysmenorrhea.
• Hormonal contraceptives alleviate dysmenorrhea by suppressing endometrial growth and prostaglandin levels.
• Treatment of underlying pathology is key for secondary dysmenorrhea; NSAIDs are effective for IUD-associated dysmenorrhea.

Conclusions:

• Primary dysmenorrhea is effectively managed with prostaglandin inhibitors or hormonal contraceptives.
• Secondary dysmenorrhea requires treatment of the specific pelvic pathology.
• Laparoscopy is indicated for suspected pelvic abnormalities or treatment-resistant cases.